Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag236 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 22.06.2026. Verfasst von Lingling Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Image Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical …. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Immunotherapy, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Province Maternal and Child Health Research.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent or metastatic cervical cancer, but responses are heterogeneous and biomarkers beyond programmed death-ligand 1 (PD-L1) are limited. Materials and Methods Targeted sequencing of 437 cancer-related genes was performed in 42 patients receiving ICI-based therapy. Genomic correlates of progression-free survival (PFS) were evaluated, and an exploratory prognostic model was developed using least absolute shrinkage and selection operator regression and multivariable Cox regression. The Cancer Genome Atlas (TCGA) cohort was used for transcriptomic analysis.
Results
The cohort included 42 patients, with a median age of 51 years; 85.7% were human papillomavirus-positive, 90.5% had squamous cell carcinoma, and 54.8% had a programmed death-ligand 1 combined positive score (PD-L1 CPS) ≥5. Frequent alterations included PIK3CA (57.1%), FBXW7 (21.4%), TERT (21.4%), BAP1 (19.0%), and EP300 (16.7%). Tumor mutational burden-associated mutations in PIK3CA, EP300, CREBBP, and TERT were associated with prolonged PFS (P < .001), whereas PD-L1–associated mutations showed numerically longer PFS (P = .170). EP300 (P = .007), PIK3CA (P < .01), and homologous recombination repair pathway alterations (P = .016) were associated with favorable PFS, whereas KEAP1 (P < .01) and TP53 (P = .010) mutations were associated with shorter PFS. A five-feature genomic model stratified patients into high- and low-risk groups (P < .001, 1-year AUC = .889). In the exploratory cohort, high-risk patients showed numerically shorter PFS (P = .060). In TCGA samples, high-risk tumors showed enrichment of angiogenesis, epithelial-mesenchymal transition, hypoxia, inflammatory response, and tumor necrosis factor-α/nuclear factor-κB signaling.
Conclusion
Specific genomic alterations may help stratify immunotherapy outcomes in recurrent or metastatic cervical cancer. The proposed genomic risk model remains exploratory and requires validation in larger, independent cervical cancer cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Image Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China.
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing 210032, China.
- Department of Nursing, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China.
ORCID-Profile: Yaqin Wu
Förderung
- National Natural Science Foundation of China
- Jiangsu Province Maternal and Child Health Research
Zitieren
APA
Gu, L., Zhu, B., Liu, C., Wu, X., Zhang, Y., Yin, J., Wang, F., Hu, T., & Wu, Y. (2026). Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag236
Vancouver
Gu L, Zhu B, Liu C, Wu X, Zhang Y, Yin J, et al. Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag236
BibTeX
@article{Gu2026,
author = {Gu, Lingling and Zhu, Biqing and Liu, Cuicui and Wu, Xiaoying and Zhang, Yaru and Yin, Jiani and Wang, Fufeng and Hu, Tingting and Wu, Yaqin},
title = {Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag236}
}
EUVIMED